Methylergometrine: comparison of plasma concentrations and clinical response of two brands.
There were no significant differences between the two brands of methylergometrine (methylergonovine), Methergin and Myomergin, in the radioimmunologically measured serum concentrations nor in the AUC after an oral 0.250 mg dose determined on the third or sixth postpartum day during a continuous treatment with methylergometrine 0.125 mg t.i.d., nor were there significant differences in the clinical response to this oxytocic drug. Peak serum concentrations were obtained at 3 hours (Methergin 6.3 nmol/1 and Myomergin 6.0 nmol/1), indicating a delayed gastrointestinal absorption in postpartum females in comparison with healthy male volunteers [6]. Spontaneous complaints of side-effects were rare and mild.
D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008755:Methylergonovine / Q000097:blood* / Q000627:therapeutic use; D006473:Postpartum Hemorrhage / Q000188:drug therapy / Q000473:pathology; D011247:Pregnancy; D013997:Time Factors; D014599:Uterus / Q000473:pathology
D008755:Methylergonovine